Dr Reddy’s Receives ANVISA Approval for Generic Semaglutide Injection in Brazil

manufacturing-news
Image Courtesy: Pixabay

Dr Reddy’s Laboratories Ltd has received marketing authorisation from Brazil’s National Health Surveillance Agency (ANVISA) for its generic semaglutide injection for the treatment of adults with inadequately controlled type 2 diabetes mellitus. The approval covers the use of semaglutide as an adjunct to diet and exercise, either as monotherapy when metformin is unsuitable due to intolerance or contraindications, or in combination with other medicines used to treat diabetes. The product will be available in pre-filled, multi-dose injection pens in two presentations: 2 mg/1.5 mL and 4 mg/3 mL, designed for once-weekly administration.

The approval marks an important step in Dr Reddy’s efforts to expand access to semaglutide across international markets. Brazil represents a significant opportunity, given the scale of diabetes in the country. An estimated 16.6 million adults aged between 20 and 79 years are living with diabetes in Brazil, placing it sixth globally in terms of the number of adults affected. The country’s semaglutide market for diabetes treatment is estimated at approximately US$244.6 million.

Commenting on the approval, MV Ramana, Chief Executive Officer, Global Generics, Dr Reddy’s Laboratories, said, “Our focus with semaglutide is to expand access to this treatment option across markets where the patient need is significant. Brazil, with its substantial burden of diabetes, is an important part of that journey. This approval builds on our broader semaglutide strategy and brings us another step closer to making semaglutide available to more patients. We plan to launch semaglutide in Brazil with Aché.”

The company plans to commercialise the product in Brazil in partnership with Aché, strengthening its presence in the country’s pharmaceutical market. The authorisation adds to Dr. Reddy’s broader efforts to make treatment options available in markets with substantial unmet healthcare needs.

Dr Reddy’s Laboratories Ltd is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company is committed to providing access to affordable and innovative medicines under its purpose, ‘Good Health Can’t Wait’. Its portfolio includes active pharmaceutical ingredients, generics, branded generics, biosimilars and over-the-counter products. Key therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include the United States, India, Russia and CIS countries, China, Brazil and Europe. The company continues to invest in science, innovation and future healthcare businesses, alongside its focus on sustainability, patient access and affordability, diversity and governance.